Bryn Pharma said today that it raised nearly $18 million in financing to fund U.S. approval and commercialization for its Bryn-NDS1C bidose epinephrine nasal spray device for treating anaphylaxis.

The $17.5 million funding round was the company’s fourth completed financing series and it included $15 million from existing and new investors, while the remaining $2.5 million came from a corporate collaborator, according to a news release.

The pocket-sized Bryn-NDS1C device is designed to contain two doses of epinephrine in one portable device, providing an easy-to-use option that eliminates the need to carry two emergency auto-injectors.

Get the full story at our sister site, Drug Delivery Business News.